Where does Xenon Pharmaceuticals's cash flow data come from?

Every line is extracted from Xenon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Net income	-$345.91M-47.6%	-$234.33M-28.5%	-$182.39M-45.5%	-$125.37M-58.9%
Depreciation and amortization	$2.54M-0.7%	$2.56M—	——	$1.41M+55.1%
Stock-based compensation	$53.71M+5.9%	$50.72M+56.7%	$32.37M+58.9%	$20.38M+103%
Deferred income taxes	-$3.2M+63.9%	-$8.86M-2,936%	-$292K—	——
Change in accounts payable	$5.51M—	——	——	$8.06M+171%
Change in other assets	——	$984K—	——	$10.5M—
Change in other liabilities	——	——	——	——
Non-cash operating lease expense	$1.31M+4.7%	$1.25M+3.4%	$1.21M+48.1%	$819K—
Change in operating lease liabilities	-$1.3M-6.3%	-$1.22M-557%	$267K+145%	-$600K—
Change in receivables	——	$614K+572%	-$130K—	——
Net cash from operating activities	-$279.12M-53.9%	-$181.39M-20.0%	-$151.11M-49.6%	-$101.03M-45.4%
Capital expenditures	$799K-74.0%	$3.08M-45.3%	$5.62M+94.1%	$2.89M+41.2%
Net cash from investing activities	$218M+32.1%	$165M+248%	-$111.39M+62.2%	-$294.72M—
Proceeds from issuance of common stock	$4.96M+10,457%	$47K+34.3%	$35K—	——
Net cash from financing activities	$117.11M+865%	$12.13M—	——	$278.47M-37.8%
Effect of exchange rate changes on cash	——	-$1.73M—	——	——
Net increase (decrease) in cash	$56.45M—	——	$96.36M+181%	-$118.45M-187%
Income taxes paid	——	——	——	——
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	-$73K+90.2%	-$745K—	——	——
Operating lease liabilities	-$1.3M-6.3%	-$1.22M-557%	$267K+145%	-$600K—
Increase (Decrease) in Other Receivables	——	——	-$130K—	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	$984K—	——	$10.5M—
Operating lease right-of-use asset amortization	$1.31M+4.7%	$1.25M+3.4%	$1.21M+48.1%	$819K—
Net proceeds from sales of subsidiary shares	——	$12.08M-96.6%	$353.49M+27.3%	$277.77M—
Proceeds From Offerings Net	$112.15M+828%	$12.08M-96.6%	$353.49M—	——
Fair Value Of Stock Options And Warrants Exercised On A Cashless Basis	$21M+153%	$8.31M+58.2%	$5.25M—	——
Fair Value Of Stock Options Exercised On Cashless Basis	——	$8.31M+58.2%	$5.25M+16.9%	$4.49M+34.1%
Increase Decrease In Operating Lease Liability	-$1.3M-6.3%	-$1.22M-557%	$267K+145%	-$600K—
Operating Lease Payments	$1.71M+2.5%	$1.67M+3.0%	$1.62M+76.7%	$919K+11.5%
Leased assets obtained in exchange for operating lease liabilities	——	——	——	$3.02M—
Free cash flow	-$279.92M-51.7%	-$184.46M-17.7%	-$156.73M-50.8%	-$103.92M-45.2%
Free cash flow	-$279.92M-51.7%	-$184.46M-17.7%	-$156.73M-50.8%	-$103.92M-45.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Xenon Pharmaceuticals's cash flow data come from?: Every line is extracted from Xenon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.